ICAD icadmed.com Final Profit

Corporate emblem and logo of icadmed.com (ICAD)

The net income metric reflects the profit dynamics of iCAD, Inc. (ICAD), where the value remains at -0.01. Growth is driven by the implementation of AI solutions for the early detection of breast cancer. However, high competition within the medtech sector and the commoditization of software pose significant risks. Stability is ensured by the unique accuracy of mammogram analysis and patent integration into global cloud services.

ICAD (iCAD Corp) Net Profit history from 07/04/2022 to 08/02/2025

Analytical breakdowns and data insights for company icadmed.com (ICAD)

- stock value and consensus price forecast:
Market Price iCAD|ICAD - Price Target Chart
- market capitalization data:
Market Value iCAD, Inc.|ICAD - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share iCAD|ICAD - Book Capitalization|Market Cap to Net Assets Ratio icadmed.com|ICAD - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital iCAD, Inc.|ICAD - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital iCAD|ICAD - Company Aggregate Debts|Debts to Book Value iCAD, Inc.|ICAD - Company Long-Term Debts|Short-Term Debt Volume iCAD|Quick Liquidity Indicator icadmed.com
- net income and valuation multiples indicators:
ICAD - Net Profit
Fundamental valuation:ICAD iCAD Corp
Manufactured product of iCAD Inc.

For iCAD, Inc. (ICAD), the company's net income reflects the final financial result after deducting all operating expenses, allowing investors to decouple actual business efficiency from market expectations. The trend of this metric confirms the monetization of proprietary AI cancer diagnostic solutions, where the integration of software into clinical protocols generates sustainable revenue and protects the issuer's market value from competition.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Financial Result sellaslifesciences.com|Net Profit ACTU (Actuate Therapeutics)|CTOR - Net Income|TuHURA - Net Profit|TARA - Net Profit|FATE: Net Profit|Company Profit WHWK|Net Income TCRX|CSBR: Final Profit|Net Profit XBIT|Net Financial Result cel-sci.com|Company Net Income OS Therapies Incorporated OSTX|RADX: Company Profit|Artiva - Net Profit|Adlai Nortye Ltd. (ANL) - Net Income|VERU (Veru Pharma) - Net Income|TPST - Net Financial Result|XLO (Xilio Therapeutics Inc) - Net Profit|Enochian BioSciences (RENB) - Net Financial Result|Net Profit MURA|Net Income kairospharma.com KAPA|Net Profit OKUR (OnKure Therapeutics)|Net Profit CytoMed Therapeutics Ltd GDTC|Curis Corp - Net Profit|APLM (Apollomics, Inc.) - Company Profit|THAR: Net Profit|Net Income Advanced Biomed|GNPX (Genprex, Inc) - Net Profit|Net Profit Calidi Bio|Company Net Income Sunshine Biopharma (SBFM)|xeneticbio.com - Company Profit|Net Profit SLRX (Salarius Pharmaceuticals, Inc.)|PPBT - Net Income|AON - Net Profit|Company Net Income BeiGene Ltd|Checkpoint Therapeutics (CKPT) - Company Net Income|Elevation Oncology Inc. - Final Profit|Net Income IKNA|NTBL: Final Profit|Net Profit VIRX|Net Income MorphoSys Corporation MOR|NAYA Biosciences - Net Income|Net Profit ascentage.com AAPGV